SEK 48.8
(-2.4%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 2.31 Billion SEK | -8.99% |
2022 | 2.54 Billion SEK | 141.98% |
2021 | 1.05 Billion SEK | 383.29% |
2020 | 217.53 Million SEK | 1100.57% |
2019 | 18.11 Million SEK | -7.54% |
2018 | 19.59 Million SEK | -23.58% |
2017 | 25.64 Million SEK | -28.9% |
2016 | 36.06 Million SEK | 85.81% |
2015 | 19.41 Million SEK | 213.5% |
2014 | 6.19 Million SEK | 184.53% |
2013 | 2.17 Million SEK | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 2.37 Billion SEK | 2.73% |
2024 Q3 | 2.25 Billion SEK | -4.45% |
2024 Q2 | 2.35 Billion SEK | -0.78% |
2023 Q1 | 2.45 Billion SEK | -3.41% |
2023 Q4 | 2.31 Billion SEK | -2.5% |
2023 FY | 2.31 Billion SEK | -8.99% |
2023 Q3 | 2.37 Billion SEK | -3.64% |
2023 Q2 | 2.46 Billion SEK | 0.28% |
2022 Q1 | 2.78 Billion SEK | 164.75% |
2022 Q3 | 2.91 Billion SEK | 0.03% |
2022 FY | 2.54 Billion SEK | 141.98% |
2022 Q2 | 2.91 Billion SEK | 4.7% |
2022 Q4 | 2.54 Billion SEK | -12.73% |
2021 Q4 | 1.05 Billion SEK | 31.7% |
2021 FY | 1.05 Billion SEK | 383.29% |
2021 Q3 | 798.28 Million SEK | 132.52% |
2021 Q2 | 343.31 Million SEK | 56.51% |
2021 Q1 | 219.35 Million SEK | 0.84% |
2020 Q3 | 98.26 Million SEK | 309.92% |
2020 FY | 217.53 Million SEK | 1100.57% |
2020 Q2 | 23.97 Million SEK | 31.07% |
2020 Q1 | 18.29 Million SEK | 0.94% |
2020 Q4 | 217.53 Million SEK | 121.37% |
2019 Q3 | 20.11 Million SEK | -12.84% |
2019 Q2 | 23.07 Million SEK | -7.86% |
2019 FY | 18.11 Million SEK | -7.54% |
2019 Q1 | 25.04 Million SEK | 27.77% |
2019 Q4 | 18.11 Million SEK | -9.9% |
2018 Q4 | 19.59 Million SEK | -13.6% |
2018 FY | 19.59 Million SEK | -23.58% |
2018 Q3 | 22.68 Million SEK | -11.32% |
2018 Q2 | 25.57 Million SEK | 0.54% |
2018 Q1 | 25.44 Million SEK | -0.79% |
2017 FY | 25.64 Million SEK | -28.9% |
2017 Q2 | 30.75 Million SEK | -10.58% |
2017 Q3 | 30.18 Million SEK | -1.83% |
2017 Q4 | 25.64 Million SEK | -15.05% |
2017 Q1 | 34.38 Million SEK | -4.66% |
2016 Q1 | 21.1 Million SEK | 8.71% |
2016 Q4 | 36.06 Million SEK | 101.29% |
2016 Q3 | 17.91 Million SEK | 5.69% |
2016 Q2 | 16.95 Million SEK | -19.66% |
2016 FY | 36.06 Million SEK | 85.81% |
2015 FY | 19.41 Million SEK | 213.5% |
2015 Q4 | 19.41 Million SEK | 0.0% |
2015 Q1 | - SEK | 0.0% |
2014 FY | 6.19 Million SEK | 184.53% |
2013 FY | 2.17 Million SEK | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
AcuCort AB | 10.97 Million SEK | -20996.128% |
AlzeCure Pharma AB (publ) | 8.22 Million SEK | -28042.701% |
BioGaia AB (publ) | 302.84 Million SEK | -664.517% |
Enzymatica AB (publ) | 49.3 Million SEK | -4596.158% |
Enorama Pharma AB (publ) | 14.84 Million SEK | -15494.396% |
Gabather AB (publ) | 6.87 Million SEK | -33562.402% |
Klaria Pharma Holding AB (publ.) | 31.98 Million SEK | -7138.479% |
Moberg Pharma AB (publ) | 24 Million SEK | -9544.27% |
Nanexa AB (publ) | 36.42 Million SEK | -6256.0% |
Newbury Pharmaceuticals AB (publ) | 38.95 Million SEK | -5843.677% |
ODI Pharma AB | 10.05 Million SEK | -22920.233% |
Orexo AB (publ) | 727.7 Million SEK | -218.167% |
Probi AB (publ) | 181.31 Million SEK | -1176.928% |
Swedish Orphan Biovitrum AB (publ) | 40.16 Billion SEK | 94.235% |
Toleranzia AB | 6.9 Million SEK | -33411.362% |
Vivesto AB | 30.45 Million SEK | -7503.113% |